Seppo Saarelainen

1.3k total citations
29 papers, 1.0k citations indexed

About

Seppo Saarelainen is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Seppo Saarelainen has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 6 papers in Molecular Biology. Recurrent topics in Seppo Saarelainen's work include Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (9 papers) and Respiratory and Cough-Related Research (3 papers). Seppo Saarelainen is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (9 papers) and Respiratory and Cough-Related Research (3 papers). Seppo Saarelainen collaborates with scholars based in Finland, United Kingdom and United States. Seppo Saarelainen's co-authors include Eeva Moilanen, Hannu Kankaanranta, Lauri Lehtimäki, Väinö Turjanmaa, Erkki Seppälä, Jóel Hasan, Markku M. Nieminen, Ritva Järvenpää, Pekka Jousilahti and Markku Heliövaara and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Peptides and Cytokine.

In The Last Decade

Seppo Saarelainen

28 papers receiving 969 citations

Peers

Countries citing papers authored by Seppo Saarelainen

Since Specialization

Citations

This map shows the geographic impact of Seppo Saarelainen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seppo Saarelainen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seppo Saarelainen more than expected).

Fields of papers citing papers by Seppo Saarelainen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seppo Saarelainen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seppo Saarelainen. The network helps show where Seppo Saarelainen may publish in the future.

Co-authorship network of co-authors of Seppo Saarelainen

This figure shows the co-authorship network connecting the top 25 collaborators of Seppo Saarelainen. A scholar is included among the top collaborators of Seppo Saarelainen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seppo Saarelainen. Seppo Saarelainen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between all-cause and cause-specific mortality and the GOLD stages 1–4: A 30-year follow-up among Finnish adults 2015 ·Respiratory Medicine ·Tiina Mattila, Tuula Vasankari, Merja Kanervisto, Tarja Laitinen, Olli Impivaara, Harri Rissanen, Paul Knekt, Pekka Jousilahti, Seppo Saarelainen, Pauli Puukka, Markku Heliövaara	20
2	Adipokines NUCB2/Nesfatin-1 and Visfatin as Novel Inflammatory Factors in Chronic Obstructive Pulmonary Disease 2014 ·Mediators of Inflammation ·(unknown), Lauri Lehtimäki, Mari Hämäläinen, Katriina Vuolteenaho, (unknown), Ritva Järvenpää, Hannu Kankaanranta, Seppo Saarelainen, Eeva Moilanen	37
3	Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD 2013 ·Respiratory Medicine ·(unknown), Lauri Lehtimäki, Katriina Vuolteenaho, Riina Nieminen, (unknown), Ritva Järvenpää, Hannu Kankaanranta, Seppo Saarelainen, Eeva Moilanen	2
4	Enhanced expression of neuropeptide S (NPS) receptor in eosinophils from severe asthmatics and subjects with total IgE above 100IU/ml 2013 ·Peptides ·Pinja Ilmarinen, Anna James, Eeva Moilanen, Ville Pulkkinen, Kameran Daham, Seppo Saarelainen, Tarja Laitinen, Sven‐Erik Dahlén, Juha Kere, Barbro Dahlén, Hannu Kankaanranta	15
5	Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma 2011 ·Journal of Inflammation ·(unknown), Lauri Lehtimäki, Katriina Vuolteenaho, Riina Nieminen, Hannu Kankaanranta, Seppo Saarelainen, Eeva Moilanen	39
6	Low socioeconomic status is associated with chronic obstructive airway diseases 2011 ·Respiratory Medicine ·Merja Kanervisto, Tuula Vasankari, Tarja Laitinen, Markku Heliövaara, Pekka Jousilahti, Seppo Saarelainen	98
7	Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients 2009 ·STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) ·Marika Crohns, Seppo Saarelainen, Marina Erhola, Hannu Alho, Pirkko Kellokumpu‐Lehtinen	2
8	Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients 2009 ·Clinical Biochemistry ·Marika Crohns, Seppo Saarelainen, Marina Erhola, Hannu Alho, Pirkko Kellokumpu‐Lehtinen	27
9	Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy 2009 ·Free Radical Research ·Marika Crohns, Seppo Saarelainen, Hannu Kankaanranta, Eeva Moilanen, Hannu Alho, Pirkko Kellokumpu‐Lehtinen	13
10	Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy — Association of interleukin-8 and VEGF with survival 2009 ·Cytokine ·Marika Crohns, Seppo Saarelainen, Seppo Laine, Tuija Poussa, Hannu Alho, Pirkko Kellokumpu‐Lehtinen	57
11	c-Jun N-terminal kinase mediates constitutive human eosinophil apoptosis 2006 ·Pulmonary Pharmacology & Therapeutics ·(unknown), Xianzhi Zhang, Seppo Saarelainen, Eeva Moilanen, Hannu Kankaanranta	12
12	Whole‐body impedance recording – a practical method for the diagnosis of sleep apnoea 2003 ·Clinical Physiology and Functional Imaging ·Seppo Saarelainen, Sari‐Leena Himanen, Jóel Hasan, Jussi Virkkala, Tiit Kööbi	3
13	Hydrogen Peroxide Reverses IL-5 Afforded Eosinophil Survival and Promotes Constitutive Human Eosinophil Apoptosis 2002 ·International Archives of Allergy and Immunology ·Hannu Kankaanranta, Mark A. Giembycz, Peter J. Barnes, El‐Bdaoui Haddad, Seppo Saarelainen, (unknown), Eeva Moilanen, Mark A. Lindsay	15
14	Extended Exhaled NO Measurement Differentiates between Alveolar and Bronchial Inflammation 2001 ·American Journal of Respiratory and Critical Care Medicine ·Lauri Lehtimäki, Hannu Kankaanranta, Seppo Saarelainen, (unknown), Ritva Järvenpää, Timo Koivula, Väinö Turjanmaa, Eeva Moilanen	155
15	Salmeterol and Fluticasone Propionate (50/250 μg) Administered via Combination Diskus Inhaler: As Effective as When Given via Separate Diskus Inhalers 1999 ·Canadian Respiratory Journal ·Kenneth R. Chapman, N Ringdal, Vibeke Backer, Mona Palmqvist, Seppo Saarelainen, M. Briggs	83
16	Autoantibodies against Oxidised Low-Density Lipoprotein in Patients with Obstructive Sleep Apnoea 1999 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Seppo Saarelainen, Terho Lehtimäki, Olli Jaakkola, Tuija Poussa, Matti Nikkilä, Tiina Solakivi, Markku M. Nieminen	25
17	No relation between apolipoprotein E alleles and obstructive sleep apnea 1998 ·Clinical Genetics ·Seppo Saarelainen, Terho Lehtimäki, (unknown), (unknown), Tuija Poussa, Markku M. Nieminen	45
18	Circulating Endothelin-1 in Obstructive Sleep Apnea 1997 ·Endothelium ·Seppo Saarelainen, Erkki Seppälä, (unknown), Jóel Hasan	77
19	Effect of nasal CPAP treatment on plasma volume, aldosterone and 24‐h blood pressure in obstructive sleep apnoea 1996 ·Journal of Sleep Research ·Seppo Saarelainen, Jóel Hasan, Simo Siitonen, Erkki Seppälä	53
20	Measurement of Respiratory Muscle Forces Based on Maximal Inspiratory and Expiratory Pressures 1994 ·Respiration ·Juha Karvonen, Seppo Saarelainen, Markku M. Nieminen	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact